Page 3 - Special Warnings News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca: WHO tritt Zweifeln am Impfstoff entgegen

AstraZeneca: WHO tritt Zweifeln am Impfstoff entgegen
orf.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from orf.at Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofNoord hollandMargaret harrisTime the companyOffice for securityDenmark hadBritisch schwedischen astrazenecaGesundheitsverwaltung reportsBeen vaccinatedSeveral countries was followedWho sprecherin margaret harrisEmea astrazeneca backedVaccine couldAnaphylaxie and

Japan versinkt im Schnee | Aktuell Asien | DW

Japan versinkt im Schnee | Aktuell Asien | DW
dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.

Japan generalYoshihide sugaAirlines japanNippon airwaysAll nippon airwaysSinojapanese television nhkSpecial warningsPrefectures fukuiShiga toyama andPublic to yoshihide sugaThe matsue burg shimaneInjured hadPrefecture of yamaguchiAirport osaka ledWinter stormHochgeschwindigkeitszugverkehr yamagata was

Japan versinkt im Schnee

Japan versinkt im Schnee
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

Japan generalChuji okuboYoshihide sugaNaoki maedaAlliance at the airportAirlines japanNippon airwaysAll nippon airwaysSinojapanese television nhkCold airAgainst and kota kawasakiStrong windsSpecial warningsPrefectures fukuiShiga toyama andPublic to yoshihide suga

Kites Tecartus (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

Posted on 10654 Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Conditional authorization is granted in the interest of public health where the benefit of immediate availability outweighs the risk of less comprehensive data available. The conditional marketing authorization is supported from the multinational, single-arm, Phase 2 open-label ZUMA-2 pivotal trial in patients with relapsed or refractory mantle cell lymphoma who had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy

City ofUnited kingdomUnited statesSanta monicaFoster cityKen takeshitaMonica telladoJohng gribbenNathan kaiserGilead sciencesEuropean commissionKite global head of clinical developmentGilead sciences incExchange commissionGilead companyRadiologic review committee

Kite s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

Share: 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe Kite, a Gilead Company (NASDAQ:GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton s tyrosine kinase (BTK) inhibitor. Conditional authorization is granted in the interest of public health where the benefit of immediate availability outweighs the risk of less comprehensive data available.

City ofUnited kingdomUnited statesSanta monicaFoster cityKen takeshitaJohng gribbenGilead sciencesEuropean commissionKite global head of clinical developmentGilead sciences incKite becomes the first companyExchange commissionGilead companyRadiologic review committeeTrial responded